Citizens Maintains Market Outperform on Evolent Health, Lowers Price Target to $11
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Constantine Davides maintains Evolent Health (NYSE:EVH) with a Market Outperform and lowers the price target from $13 to $11.
Citizens analyst Constantine Davides maintains Evolent Health (NYSE:EVH) with a Market Outperform and lowers the price target from $13 to $11.